William Blair Has Negative Outlook of Medtronic Q3 Earnings

Medtronic plc (NYSE:MDT) – Analysts at William Blair lowered their Q3 2025 earnings estimates for Medtronic in a report released on Tuesday, November 19th. William Blair analyst M. Andrew now expects that the medical technology company will earn $1.36 per share for the quarter, down from their prior forecast of $1.37. The consensus estimate for Medtronic’s current full-year earnings is $5.46 per share. William Blair also issued estimates for Medtronic’s Q4 2025 earnings at $1.62 EPS, FY2025 earnings at $5.46 EPS and Q2 2026 earnings at $1.43 EPS.

A number of other research analysts have also commented on the stock. Oppenheimer upped their price objective on shares of Medtronic from $92.00 to $94.00 and gave the company a “market perform” rating in a research report on Wednesday, August 21st. UBS Group upgraded shares of Medtronic from a “sell” rating to a “neutral” rating and raised their price target for the stock from $76.00 to $90.00 in a research note on Thursday, August 15th. Piper Sandler raised their target price on Medtronic from $85.00 to $90.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 21st. Daiwa America upgraded Medtronic to a “strong-buy” rating in a research report on Friday, August 23rd. Finally, Stifel Nicolaus boosted their target price on shares of Medtronic from $85.00 to $87.00 and gave the company a “hold” rating in a research note on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $95.19.

Medtronic Trading Down 1.0 %

Shares of Medtronic stock opened at $84.11 on Thursday. The company has a market cap of $107.87 billion, a price-to-earnings ratio of 25.72, a PEG ratio of 2.42 and a beta of 0.84. Medtronic has a 1 year low of $75.96 and a 1 year high of $92.68. The company’s fifty day simple moving average is $89.17 and its 200-day simple moving average is $84.84. The company has a current ratio of 1.84, a quick ratio of 1.61 and a debt-to-equity ratio of 0.51.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.01. Medtronic had a return on equity of 13.79% and a net margin of 13.00%. The firm had revenue of $8.40 billion during the quarter, compared to analyst estimates of $8.27 billion. During the same period in the previous year, the company earned $1.25 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Olstein Capital Management L.P. lifted its holdings in Medtronic by 19.2% during the third quarter. Olstein Capital Management L.P. now owns 87,000 shares of the medical technology company’s stock worth $7,833,000 after acquiring an additional 14,000 shares in the last quarter. Manning & Napier Advisors LLC bought a new position in Medtronic in the second quarter valued at approximately $25,643,000. Ferguson Wellman Capital Management Inc. acquired a new position in shares of Medtronic in the third quarter valued at approximately $9,486,000. Harvest Portfolios Group Inc. boosted its stake in Medtronic by 6.5% in the 3rd quarter. Harvest Portfolios Group Inc. now owns 689,131 shares of the medical technology company’s stock worth $62,042,000 after purchasing an additional 42,112 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its position in shares of Medtronic by 6.3% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 368,682 shares of the medical technology company’s stock worth $29,019,000 after purchasing an additional 21,995 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.